H.C. Wainwright lowered the firm’s price target on Nurix Therapeutics (NRIX) to $33 from $34 and keeps a Buy rating on the shares following the Q3 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Reports Increased Losses Amid R&D Expansion
- Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo
- Nurix Therapeutics price target lowered to $33 from $35 at Stifel
- 3 Best Stocks to Buy Now, 10/10/2025, According to Top Analysts
- Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer